Keyphrases
5-year Survival
15%
BRAF mutation
8%
Cancer-specific Survival
6%
Carbohydrate Antigen 19-9 (CA19-9)
6%
Carcinoembryonic Antigen
22%
Carcinoembryonic Antigen Levels
12%
Cell-free DNA (cfDNA)
8%
Cetuximab
6%
Chemotherapy
18%
Clinical Significance
16%
Colon Cancer
16%
Colorectal Adenocarcinoma
7%
Colorectal Cancer
100%
Colorectal Cancer Patients
56%
Confidence Interval
6%
Curative Resection
6%
Curative Surgery
12%
Disease-free Survival
16%
Elevated Microsatellite Alteration at Selected Tetranucleotide Repeats (EMAST)
6%
Gastric Cancer
12%
Gastric Cancer Patients
8%
General Hospital
12%
Genetic Modification
9%
Hazard Ratio
8%
Hypermethylation
12%
Independent Prognostic Factor
11%
KRAS mutation
9%
Lymph Node Metastasis
9%
Lymphovascular Invasion
10%
Metastatic Colorectal Cancer (mCRC)
30%
Microsatellite Instability-high (MSI-H)
35%
Microsatellite Stable
7%
Molecular Differences
6%
Multivariate Analysis
13%
Mutation Spectrum
7%
Overall Survival
26%
Patient Outcomes
8%
Patients with Colorectal Cancer
18%
Prognostic Biomarker
6%
Prognostic Factors
12%
Prognostic Value
10%
Right-sided Colon Cancer
15%
Sporadic Colorectal Cancer
8%
Stage II Colorectal Cancer
6%
Synchronous Colorectal Cancer
6%
Taipei
12%
Taiwan
14%
TNM Staging
6%
Tumor
35%
Univariate Analysis
6%
Medicine and Dentistry
Abdominal Cancer
12%
Adenocarcinoma
5%
Biological Marker
8%
CA 19-9 Antigen
6%
Carcinoembryonic Antigen
18%
Carcinogenesis
5%
Cell-Free DNA
5%
Chemoradiotherapy
7%
Chemotherapy
16%
Colon
5%
Colon Carcinoma
28%
Colorectal Carcinoma
99%
Disease
27%
Disease Free Survival
15%
Distant Metastasis
5%
Gene Mutation
9%
Liver Metastasis
8%
Lymph Node
7%
Lymph Node Metastasis
8%
Lymphovascular Invasion
8%
Malignant Neoplasm
11%
Metastasectomy
12%
Metastatic Carcinoma
15%
Metastatic Colorectal Cancer
6%
Microsatellite Instability
11%
Multivariate Analysis
8%
Neoplasm
35%
Overall Survival
23%
Primary Tumor
9%
Prognostic Factor
15%
Proportional Hazards Model
6%
Rectum Cancer
21%
Recurrent Disease
13%
Surgery
17%
Survival Rate
12%
Univariate Analysis
5%